NCT00811356View on ClinicalTrials.gov

A First Time in Human Study in Healthy Volunteers to Investigate a New Medicine to Treat Malaria

PHASE1TerminatedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

December 11, 2008

Primary Completion Date

March 30, 2009

Study Completion Date

March 30, 2009

Conditions
Malaria
Interventions
DRUG

GSK932121; Rosiglitazone; Rosuvastatin

GSK932121 is the study drug that will be tested in all parts of this study as described above. Rosiglitazone and rosuvastatin will only be tested in the drug-drug interaction substudy.

Trial Locations (1)

3004

GSK Investigational Site, Melbourne

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY